Melanocytes are specialized pigmented cells that are found in all healthy skin tissue. In certain individuals, diseased melanocytes can form malignant tumours, melanomas, which cause the majority of skin-cancer-related deaths. The melanoma-associated antigenic peptides are presented on cell surfaces via the class I major histocompatibility complex (MHC). Among the melanomaassociated antigens, the melanoma self-antigen A/melanoma antigen recognized by T cells (Melan-A/MART-1) has attracted attention because of its wide expression in primary and metastatic melanomas. Here, a preliminary X-ray crystal structural study of a soluble cognate T-cell receptor (TCR) in complex with a pMHC presenting the Melan-A peptide (ELAGIGILTV) is reported. The TCR and pMHC were refolded, purified and mixed together to form complexes, which were crystallized using the sitting-drop vapour-diffusion method. Single TCR-pMHC complex crystals were cryocooled and used for data collection. Diffraction data showed that these crystals belonged to space group P4 1 /P4 3 , with unit-cell parameters a = b = 120.4, c = 81.6 Å . A complete data set was collected to 3.1 Å and the structure is currently being analysed.
Introduction
Melanocytes are specialized pigmented cells that are widespread in skin and eye tissue (Gray-Schopfer et al., 2007) . The degree of pigment production manifests as skin 'phototype' (skin colour and ease of tanning) and is the most useful predictor of human skincancer risk in the general population (Maresca et al., 2006) . The main contributors to pigmentation are melanins, which are produced by melanocytes (Gray-Schopfer et al., 2007) . The skin provides photoprotection and thermoregulation by using melanin. Thus, melanocytes play a key role in protecting our skin from the damaging effects of UV radiation and in preventing skin cancer, which occurs at an estimated 2-3 million cases across the world each year.
The first identified melanoma antigen recognized by T cells (MART) presented by class I MHC was MAGE (van der Bruggen et al., 1991) . Molecular characterizations of the antigens Melan-A/ MART-1, gp100 and tyrosinase were subsequently reported (Coulie et al., 1994; Kawakami, Eliyahu, Delgado, Robbins, Rivoltini et al., 1994; Kawakami, Eliyahu, Delgado, Robbins, Sakaguchi et al., 1994) . In order to increase the weak immunogenicity of these antigens, attempts were made to modify them: for example, Melan-A/MART-1 26-35 and gp100 209-217 (Parkhurst et al., 1996; Valmori et al., 1998) . Some modifications generated stronger T-cell responses to both wildtype and modified peptides, whilst other modifications resulted in an increased response to modified peptides only. How T-cell receptor (TCR) molecules recognize these presented antigens remains unclear. Previous work has focused on the mechanisms of melanomaantigen presentation by MHC complexes (Sliz et al., 2001; Hü lsmeyer et al., 2005) .
Among the many melanoma-associated antigens, Melan-A/ MART-1 has attracted attention because of its wide expression in primary and metastatic melanomas. It is recognized by about 90% of tumour-infiltrating lymphocytes (TILs) originating from HLA-A*0201 patients (Parmiani, 2001) . We therefore isolated a TCR from # 2007 International Union of Crystallography All rights reserved a Melan-A-specific CD8 + T-cell clone that recognizes the ELAGI-GILTV peptide in complex with HLA-A*0201 and crystallized the trimolecular complex.
Materials and methods

Protein expression
The cDNAs of the TCR -and -chains from Melan-A CD8 + T-cell clone Mel5 were isolated using reverse transcription (V12-2, TRAJ27 and V30, TRBJ2-2). The TCR chains were amplified by polymerase chain reaction and cloned into the pGMT7 Escherichia coli expression system as described previously, with mutations to cysteine at Cys48 and Cys57 and mutation of alanine to Cys75 (Boulter et al., 2003) . The extracellular domain of HLA-A*0201 and 2m were cloned into the pGMT7 system as described previously (Gao et al., 1997) .
The plasmids were transformed into E. coli Rosetta DE3 competent cells and transformed cells were used to inoculate 1 l TYP media containing ampicillin (100 mg ml
À1
). 1 mM IPTG (isopropyl -dthiogalactopyranoside) was used to induce expression for 5 h before harvesting the cells by centrifugation. The cell pellets were sonicated in lysis buffer (10 mM Tris-HCl pH 8.0, 150 mM NaCl, 10 mM EDTA, 2 mM DTT, 0.5 mM PMSF, 100-400 mg ml À1 lysozyme, 10% glycerol, 20 mg ml À1 DNAse I) and centrifuged to remove soluble debris. The resulting inclusion bodies were washed with Triton buffer (0.5% Triton X-100, 50 mM Tris-HCl pH 8.0, 100 mM NaCl, 0.1% sodium azide, 10 mM EDTA, 2 mM DTT) and further washed with resuspension buffer (50 mM Tris-HCl pH 8.0, 100 mM NaCl, 10 mM EDTA, 2 mM DTT). The washed TCR inclusion bodies were then dissolved in guanidine buffer (6 M guanidine, 50 mM Tris-HCl pH 8.0, 100 mM NaCl, 10 mM EDTA and 10 mM DTT). MHC and 2m inclusion bodies were separately dissolved in a solution of 10 mM Tris-HCl pH 8.0, 8 M urea and 10 mM DTT. The purity of the inclusion bodies was assessed by SDS-PAGE.
Protein refolding and purification
pMHC and TCR protein refolding was carried out as described previously (Gao et al., 1997; Boulter et al., 2003) . Briefly, 60 mg guanidine-solubilized -and -chain inclusion bodies were mixed in a 1:1 molar ratio and refolded by rapid dilution into 1 l refolding buffer (5 M urea, 0.4 M l-arginine, 100 mM Tris pH 8.1, 3.7 mM cystamine, 6.6 mM -mercaptoethylamine) at 277 K. For pMHC refolding, the peptide was dissolved in DMSO. HLA-A*0201 heavy chain, 2m and peptide were mixed in a 1:1:3 molecular ratio with a rapid dilution into 0.4 M l-arginine, 100 mM Tris pH 8.0, 2 mM EDTA, 3.7 mM cystamine and 6.6 mM -mercaptoethylamine. Solutions were mixed at 277 K for at least 1 h. Dialysis was conducted against 10 mM TrisHCl pH 8.1 until the conductivity of the two refolds was less than 1 mS cm
À1
. The refolded proteins were filtered (0.2 mm) and purified by ionexchange chromatography (POROS 50HQ column, PerSeptive Biosystems Inc.) and gel-filtration chromatography (Superdex-75HR, GE Healthcare) into crystallization buffer (10 mM Tris-HCl pH 8.1, 10 mM NaCl). The proteins were then separately concentrated to approximately 10 mg ml À1 using 10 kDa centrifugal concentrators prior to mixing to form the complex for crystallization.
Crystallization
Concentrated TCR and pMHC were mixed in a 1:1 molecular ratio. Crystal screening was initiated using Hampton Research Crystal Screens 1, 2 and Cryo 1 with drops consisting of 1 ml protein solution and 1 ml crystallization buffer using the hanging-drop method. Plates were incubated at 293 K and were analysed after 24 h, 48 h and one week. Further crystal screens were automated at the Structural Biology Laboratory, Daresbury using the Innovadyne Screenmaker 96+8 with Qiagen Nextal crystallization coarse screen solutions. Needle-shaped crystals were observed in a variety of conditions from Nextal PEGs Suite and Cryos suite after 5 d incubation at 293 K, but with poor diffraction of up to 30 Å resolution.
Optimized crystallization conditions were obtained using an array of PEG solutions (10-30% PEG 550 MME and PEG 400 pH 6.5-8.5, 15% glycerol) prepared using a Hamilton Microlab STAR LET liquidhandling robot. Crystals (Fig. 1) were harvested from 23% PEG 550 MME, 0.1 M Tris pH 7.4 and 15% glycerol after incubation at 293 K for three weeks.
Data collection and processing
Data were collected using the rotation method at SRS Station 14.2, Daresbury, UK with an ADSC Quantum 4 CCD-detector system. The wavelength was set to 0.979 Å . A total of 200 frames were recorded, each covering 0.5 of rotation. The crystal was maintained at 100 K in an Oxford Cryostream. Reflection intensities were estimated using the MOSFLM package (Leslie, 1992) and the data were scaled, reduced and analysed with SCALA and the CCP4 package (Collaborative Computational Project, Number 4, 1994) . Crystal data and relevant statistics are given in Table 1 .
Results and discussion
The pMHC-TCR complex crystals were analysed by X-ray diffraction and found to belong to space group P4 1 /P4 3 , as deduced from Typical appearance of crystals in the sitting drops. systematic absences, with unit-cell parameters a = b = 120.4, c = 81.6 Å (Table 1) . One molecule of the complex can be accommodated per asymmetric unit, giving a V M value of 3.1 Å 3 Da À1 and a solvent content of 60.5%. A full data set was collected to 3.1 Å resolution. A total of 81 690 observations were measured, including 21 332 unique reflections. The completeness was 99.8%, with a multiplicity of 3.8 and an R sym of 20.0%. The R sym statistic is relatively high, but the resolution cutoff was determined by an I/(I) value of 2.1 in the outermost shell, which is acceptable for most applications, particularly with the reasonably high multiplicity of 3.9 in that shell. Considering that the present work is the result of two rounds of optimization and screening of a number of crystals, it may be considered an achievement to obtain this quality of data.
Structure determination and refinement is currently under way.
